Quest Magazine

MDA Adds Neurological Disease Expert to Research Team

Lianna R. Orlando, Ph.D of Harvard University named Scientific Program Officer

Lowe’s Reaches $50 Million Mark in Support of MDA

Stores Nationwide Raise More Than $7.5 Million during 2015
Shamrock Program to Help Improve Lives in MDA Communities


MDA Leader and Former National Ambassador Ben Cumbo Mourned by Muscular Dystrophy Community

MDA joins the larger disability community in mourning the loss of Benjamin Cumbo IV, who died yesterday at age 27.

Santhera Reports Positive Phase III Clinical Trial Results for Raxone®/Cantana® (idebenone) for the Treatment of Duchenne Muscular Dystrophy

MDA Families and Leadership Advocate in Washington, D.C.

BioBlast Pharma Receives FDA Fast Track Designation for Treatment of Oculopharyngeal Muscular Dystrophy

Santhera Receives FDA Fast Track Designation for Treatment of Duchenne Muscular Dystrophy

Kroger-Atlanta Division Raises More Than $292,000 Through MDA Shamrock Program To Help People Fighting Muscle Disease

MDA Ride for Life XXVIII Partners with Camelback Resort in the Fight Against Muscle Disease

ALS Research Update: Spring 2015

Understanding the many roads that can lead to amyotrophic lateral sclerosis (ALS) is a painstaking but necessary prerequisite to development of disease-modifying treatments. Recently, several research teams have made contributions to this effort. A 2011 MDA career development grant to Adrian Israelson, who was then at the University of California, San Diego, was crucial to the finding that the MIF protein counteracts the effects of ALS-causing mutations in the SOD1 gene.